trastuzumab deruxtecan,atezolizumab,dkn-01
daiichi sankyo,leap therapeutics,roche,astrazeneca
['waking', 'distinguish', 'prostate', '$lptx', 'roche,(-broche),(-rocheter)']
4/5 $lptx endometrial cancer had a complete response in monotherapy; and prostate. esmo poster presentation from their distinguish study being released tomorrow morning; oral presentation on monday. roche is also partnered with them and paying for the waking clinical study.
Biotech enthusiast, founder law firm Goldman Hine LLP (retired Jan 2021),CEO Comstock Metals, advisor to E3 Lithium (ETL.V), BA, JD, contributor Seeking Alpha